Abstract: The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo.
Type:
Grant
Filed:
December 17, 2015
Date of Patent:
March 27, 2018
Assignees:
Oregon Health & Science University, The United States of America as represented by the Deparment of Veterans Affairs
Inventors:
Gregory G. Burrows, Arthur A. Vandenbark